| scholarly article | Q13442814 |
| P2093 | author name string | Li Ma | |
| Ming Yao | |||
| Kan He | |||
| Lifei Wang | |||
| Donglu Zhang | |||
| W Griffith Humphreys | |||
| Theunis C Goosen | |||
| Nirmala Raghavan | |||
| Scott J Grossman | |||
| Brad D Maxwell | |||
| Charles E Frost | |||
| Shiang-yuan Chen | |||
| P433 | issue | 3 | |
| P921 | main subject | apixaban | Q414462 |
| drug interaction | Q718753 | ||
| drug metabolism | Q1124842 | ||
| P304 | page(s) | 448-458 | |
| P577 | publication date | 2009-11-25 | |
| P1433 | published in | Drug Metabolism and Disposition | Q1261140 |
| P1476 | title | In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies | |
| P478 | volume | 38 |
| Q37312021 | A new era of stroke prevention in atrial fibrillation: comparing a new generation of oral anticoagulants with warfarin |
| Q37953152 | Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence |
| Q37980250 | Apixaban for the prevention of stroke in atrial fibrillation |
| Q37765608 | Apixaban in acute coronary syndromes |
| Q37495983 | Apixaban in patients with Atrial Fibrillation: A Systematic Review |
| Q38566808 | Apixaban versus edoxaban for stroke prevention in nonvalvular atrial fibrillation |
| Q40726048 | Apixaban versus enoxaparin in the prevention of venous thromboembolism following total knee arthroplasty: a single-centre, single-surgeon, retrospective analysis |
| Q92028447 | Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review |
| Q38020739 | Apixaban: a novel oral inhibitor of factor Xa. |
| Q38107180 | Apixaban: a review of its use for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation |
| Q38017736 | Apixaban: a review of its use in the prevention of venous thromboembolism after knee or hip replacement surgery |
| Q37987051 | Apixaban: an oral direct factor-xa inhibitor |
| Q85068498 | Apixaban: first global approval |
| Q90232755 | Application of a microdosed cocktail of 3 oral factor Xa inhibitors to study drug-drug interactions with different perpetrator drugs |
| Q37263390 | CYP2J2 and CYP2C19 are the major enzymes responsible for metabolism of albendazole and fenbendazole in human liver microsomes and recombinant P450 assay systems |
| Q48088971 | Characterization of Phase I and Phase II Hepatic Metabolism and Reactive Intermediates of Larrea nitida Cav. and Its Lignan Compounds |
| Q37609046 | Clinical strategies for selecting oral anticoagulants in patients with atrial fibrillation. |
| Q38156338 | Concerns about the use of new oral anticoagulants for stroke prevention in elderly patients with atrial fibrillation |
| Q38253961 | Consideration of clinical variables for choosing new anticoagulant alternatives to warfarin for the management of non-valvular atrial fibrillation |
| Q34358307 | Cytochrome P450 2J2: distribution, function, regulation, genetic polymorphisms and clinical significance |
| Q39028122 | Direct Oral Anticoagulants: An Overview for the Interventional Radiologist |
| Q38269003 | Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review. |
| Q38087189 | Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation |
| Q37848142 | Drug and dietary interactions of warfarin and novel oral anticoagulants: an update |
| Q90348789 | Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care |
| Q38194963 | Drug interactions between antiplatelet or novel oral anticoagulant medications and antiretroviral medications |
| Q53925224 | Drug therapy in anticoagulation: which drug for which patient? |
| Q89418915 | Drug-Drug Interaction Study of Apixaban with Cyclosporine and Tacrolimus in Healthy Volunteers |
| Q38830358 | Drug-drug interactions of non-vitamin K oral anticoagulants |
| Q37699699 | Edoxaban in Atrial Fibrillation and Venous Thromboembolism-Ten Key Questions and Answers: A Practical Guide. |
| Q53218072 | Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa. |
| Q37353441 | Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects |
| Q36797336 | Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor |
| Q35557449 | Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor |
| Q35666219 | Effects of age and sex on the single-dose pharmacokinetics and pharmacodynamics of apixaban |
| Q34651051 | European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation |
| Q34554473 | Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban |
| Q93377864 | Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjects |
| Q28076077 | Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment |
| Q26776413 | How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillation |
| Q37850800 | Investigational factor Xa inhibitors for thrombosis and acute coronary syndromes. |
| Q50896785 | Italian intersociety consensus on DOAC use in internal medicine. |
| Q37834646 | Laboratory assessment of new anticoagulants |
| Q89861393 | Large Volume Direct Injection Ultra-High Performance Liquid Chromatography-Tandem Mass Spectrometry-Based Comparative Pharmacokinetic Study between Single and Combinatory Uses of Carthamus tinctorius Extract and Notoginseng Total Saponins |
| Q26766303 | Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy |
| Q28066141 | New Oral Anticoagulants in Nonvalvular Atrial Fibrillation |
| Q33397359 | New and emerging anticoagulant therapy for atrial fibrillation and acute coronary syndrome |
| Q38988927 | New oral anticoagulants for thromboprophylaxis after elective total hip and knee arthroplasty |
| Q42822213 | New oral anticoagulants from the perspective of trauma surgery |
| Q40580512 | New oral anticoagulants in the treatment of pulmonary embolism: efficacy, bleeding risk, and monitoring |
| Q42920623 | New oral anticoagulants: better than vitamin K antagonists? |
| Q38071973 | New oral anticoagulants: comparative pharmacology with vitamin K antagonists |
| Q28080616 | New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events |
| Q36100271 | Non-vitamin K antagonist oral anticoagulants: new choices for patient management in atrial fibrillation |
| Q38838530 | Novel Oral Anticoagulants in Atrial Fibrillation: Update on Apixaban. |
| Q38155933 | Novel anticoagulants for stroke prevention in atrial fibrillation: safety issues in the elderly |
| Q36443814 | Novel anticoagulants in atrial fibrillation stroke prevention |
| Q38076076 | Oral anticoagulants in older adults with atrial fibrillation |
| Q43594298 | Oral factor Xa inhibitors for the long-term management of ACS. |
| Q38129965 | Personalizing oral anticoagulant treatment in patients with atrial fibrillation |
| Q38386660 | Pharmacodynamic profile and drug interactions with non-vitamin K antagonist oral anticoagulants: implications for patients with atrial fibrillation |
| Q23919667 | Pharmacogenetics, pharmacogenomics, and individualized medicine |
| Q37495788 | Pharmacological Therapy in Stroke Prophylaxis - The New versus the Old Agents |
| Q38104314 | Pharmacology of the new target-specific oral anticoagulants |
| Q64977733 | Population Pharmacokinetics of Apixaban in Subjects With Nonvalvular Atrial Fibrillation. |
| Q33729811 | Population Pharmacokinetics, Pharmacodynamics, and Exploratory Exposure-Response Analyses of Apixaban in Subjects Treated for Venous Thromboembolism |
| Q49850586 | Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with atrial fibrillation. |
| Q36839479 | Potential role of new anticoagulants for prevention and treatment of venous thromboembolism in cancer patients. |
| Q37338120 | Practical management of new oral anticoagulants after total hip or total knee arthroplasty |
| Q37841256 | Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor |
| Q52838335 | Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor. |
| Q41930344 | Recent advances in the management of venous thromboembolism |
| Q36933789 | Role of apixaban (eliquis) in the treatment and prevention of thromboembolic disease |
| Q26764874 | Safety of apixaban for venous thromboembolism prophylaxis: the evidence to date |
| Q37369329 | Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects |
| Q37388373 | Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects |
| Q26781181 | Stroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulants |
| Q38307541 | Target-specific oral anticoagulants and the hospitalist |
| Q40033422 | The European Heart Rhythm Association Practical Guide on the Use of New Oral Anticoagulants in Patients with Non-valvular Atrial Fibrillation - A Brief Summary |
| Q38792322 | The Role of Nonvitamin K Antagonist Oral Anticoagulants (NOACs) in Stroke Prevention in Patients with Atrial Fibrillation |
| Q54961174 | The Significance of Drug-Drug and Drug-Food Interactions of Oral Anticoagulation. |
| Q37669187 | The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects |
| Q38750444 | The genetic basis of antiplatelet and anticoagulant therapy: A pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban). |
| Q38189788 | The new factor Xa inhibitor: Apixaban |
| Q37939851 | The role of apixaban for venous and arterial thromboembolic disease |
| Q26828439 | The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery |
| Q37851981 | Toward a new age of cellular pharmacokinetics in drug discovery |
| Q92977571 | Unexpected excessive apixaban exposure: case report of a patient with polymorphisms of multiple apixaban elimination pathways |
| Q84007372 | [New anticoagulants for stroke prevention in atrial fibrillation] |
| Q84080026 | [Pharmacology of the new oral anticoagulants] |
Search more.